Dongin (Donoven) Kim, Ph.D.
Assistant Professor
Pharmaceutical Sciences
Phone (405) 271-6593 x 47473
Alt Phone (801) 574-6823 (cell)
Office College of Pharmacy, CPB 317
Email dongin-kim@ouhsc.edu
Publications & Presentations
- 16. Arun Kumar S, Good J, Hendrix D, Yoo E, Kim D, Deo K A, Jhan Y Y, Gaharwar A K, Bishop C J. Nanoengineered Light-Activatable Polybubbles for On-Demand Therapeutic Delivery. Advanced functional materials. 2020; 30 : 2003579
17. Kang C, Kim D. Nanoconfinement-mediated cancer theranostics. Archives of pharmacal research. 2020; 43 : 110-117
18. Yoo D, Jung E, Noh J, Hyun H, Seon S, Hong S, Kim D, Lee D. Glutathione-Depleting Pro-Oxidant as a Selective Anticancer Therapeutic Agent. ACS omega. 2019; 4 : 10070-10077
19. Ash G I, Kim D, Choudhury M. Promises of Nanotherapeutics in Obesity. Trends in endocrinology and metabolism: TEM. 2019; 30 : 369-383
20. Whang C H, Yoo E, Hur S K, Kim K S, Kim D, Jo S. A highly GSH-sensitive SN-38 prodrug with an "OFF-to-ON" fluorescence switch as a bifunctional anticancer agent. Chemical communications (Cambridge, England). 2018; 54 : 9031-9034
Grants
- 1. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.
2. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.
3. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
4. Lymphatics and lymphangiogenesis in kidney function and inflammation. NIH. Start Date: 2019. End Date: 2024.
5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
Awards and Honors
no results
Education
- 1. Degree: Ph D. University of Utah. Date: 2009.
2. Degree: MS. University of Florida. Date: 2002.
3. Degree: BS. Ajou University. Date: 1999.
Administrative Assignments
no results